Lab monitoring is not required for psoriasis patients treated with deucravacitinib (Sotyktu, BMS), according to a new expert consensus panel. In this video, study author Milaan Shah, MD, a Dermatology Resident at the Medical University of South Carolina in Charleston, SC, reviews the findings, which are published in the February 2025 issue of the Journal of Drugs in Dermatology.
